KFDA approves Clozaril as new use for reducing risk of suicidal behavior

Published: 2003-11-27 06:59:00

Updated: 2003-11-27 06:59:00

The Korea Food and Drug Administration has recently approved a new use for the schizophrenia drug, Clozaril, for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.

Earlier, Clozaril was approved for treatment of schizophrenia in patien...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK